InvestigationalLate-stage / investigational

Cagrilintide + semaglutide

Also known as:CagriSema

Class: Late-stage / investigational
Route: SC injection
Frequency: Once weekly in trials
GLP-1 relevance: Yes

How it works

Amylin analog + GLP-1 receptor agonist combination

Approved & studied uses

Obesity; type 2 diabetes pipeline

Regulatory status

Investigational — not FDA-approved as of 4 August 2026; submitted for US regulatory review, status varies by jurisdiction

Safety notes

Separate products should not be combined outside an approved, prescribed combination product.

Sources

CagriSema ClinicalTrials
CagriSema Novo release

Educational reference only. This page does not provide diagnosis, dosing, titration or treatment recommendations. Peptimize does not recommend or adjust any medication schedule - that is between you and your prescriber.